Actionable news
0
All posts from Actionable news
Actionable news in PRGO: PERRIGO COMPANY PLC,

Prospectuses and communications, business combinations

BGCOLOR="WHITE">

Pursuant to Rule 425 under the Securities Act of 1933

Subject Company:

Perrigo Company plc

Commission File No. 001-36353

Mylan Highly Confident in Successful Completion of Tender Offer for Perrigo on Friday

Mylans Offer Worth Approximately $44 More Than Perrigos Hypothetical Standalone Share Price

Mylan Reminds Perrigo Shareholders that Tendering Before the November 13, 2015 8:00 AM ET Deadline is the Best Way to Ensure They Receive the Immediate Premium, Accretion and Value Creation from Mylans Offer

Reminds Perrigo Shareholders that Greater than 50% of Shares Outstanding Must be Tendered by November 13 Deadline for Offer to be Extended

Perrigo Ineligible for Index Inclusion if Mylan Offer Prevails

HERTFORDSHIRE, England and PITTSBURGH, Nov. 10, 2015 Mylan N.V. (NASDAQ: MYL; TASE) today reminded shareholders of Perrigo Company plc (NYSE: PRGO; TASE) that its offer to acquire all outstanding shares of Perrigo will expire on November 13, 2015 at 8:00 AM Eastern Time.

Mylan reminds Perrigo shareholders that if the greater than 50 percent acceptance condition is not satisfied by November 13, 2015 at 8:00 AM ET, its offer will lapse and there will be no subsequent offer period. Mylan encourages Perrigo shareholders to tender by the close of business on Thursday, November 12, 2015 to avoid losing the opportunity to realize the benefits of its compelling offer. If the tender is successful, Perrigo shareholders whose tenders are received by 8:00 AM ET Friday are expected to receive their consideration by Wednesday, November 18, 2015.

Mylan also reminds Perrigo shareholders of the significant benefits of the Mylan offer and provides clarity on certain elements of the tender process. Key highlights include:

Mylan encourages Perrigo shareholders to review its presentations dated October 30, 2015 and November 4, 2015, which are available at perrigotransaction.mylan.com and www.sec.gov for more information.

On November 3, 2015 Mylan achieved the final regulatory clearance needed by Mylan to close its acquisition of Perrigo. This represented the last remaining condition that needed to be satisfied for the successful completion of the offer other than the Perrigo shareholder acceptance condition.

Mylan has appointed Innisfree M&A Incorporated, along with its London-based subsidiary, Lake Isle M&A Incorporated, as Information Agent with respect to the Offer.

If shareholders have any questions, or need assistance, please contact:

Innisfree M&A Incorporated (New York):

Frank Lentini (+1 212 750 7946)

Lloyd Lefcourt (+1 212 750 7419)

Lake Isle M&A Incorporated (London):

Solange Neitzel (+44 (0)20 7710 9963)

Under the terms of Mylans offer, Perrigo shareholders will receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share. On September 14, 2015 Mylan officially commenced its formal offer to acquire all outstanding ordinary shares of Perrigo.

The offer is being made in accordance with Mylans announcement (dated April 24, 2015 and amended on April 29, 2015 and on August 13, 2015) pursuant to Rule 2.5 of the Irish Takeover Rules that set forth Mylans legally binding commitment to commence an offer and the Offer to Exchange / Prospectus (being the offer document for the purposes of the Irish Takeover Rules) dated September 14, 2015. The offer and withdrawal rights are scheduled to expire at 1:00 P.M. (Irish time)/8:00 A.M. (New York City time) on November 13, 2015, unless the offer is extended with the consent of the Irish Takeover Panel. The acceptance condition for the offer requires greater than 50% of Perrigo ordinary shares to have been tendered into the offer.

A copy of the Offer to Exchange/Prospectus and other related materials have been mailed to Perrigo shareholders and the Offer to Exchange/Prospectus is available at perrigotransaction.mylan.com.

ABOUT MYLAN

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do whats right, not whats easy; and impact the future through passionate global leadership. We offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which nearly 50% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. Our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com.

FORWARD-LOOKING STATEMENTS

This communication contains forward-looking statements. Such forward-looking statements may include, without limitation, statements about the proposed acquisition of Perrigo Company plc (Perrigo) by Mylan N.V. (Mylan) (the Perrigo Proposal), Mylans acquisition (the EPD Transaction) of Mylan Inc. and Abbott Laboratories non-U.S. developed markets specialty and branded generics business (the EPD Business), the benefits and synergies of the Perrigo Proposal or EPD Transaction, future opportunities for Mylan, Perrigo, or the combined company and products, and any other statements regarding Mylans, Perrigos, or the combined companys future operations, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competition, and other expectations and targets for future periods. These may often be identified by the use of words such as will, may, could, should, would, project, believe, anticipate, expect, plan, estimate, forecast, potential, intend, continue, target and variations of these words or comparable...


More